ALK and non-small cell lung carcinoma: The patients’ median age was 71 years, 58.1% were male, 51.4% had an ECOG PS of 0, 89.5% had stage IV NSCLC, 37.1% had an EGFR exon 19 mutation, 15.2% had an EGFR exon 21 mutation, none had an ALK translocation, 43.8% had bone metastases, 58.1% were never smokers, and 40% had coexisting morbidities.